The vascular endothelial growth factor (VEGF) has been considered as the major angiogenic stimulus for ocular neovascularization.1–6 Bevacizumab (Avastin), a full - length humanized monoclonal antibody, binds to and inhibits all biologically active isoforms of VEGF-A.1,7 Although FDA-approved only for intravenous administration in the treatment of metastatic colorectal cancer and other malignant tumors, this drug is widely used off-label in various ophthalmic conditions. Here, VEGFA is linked to cancer.